<bill session="111" type="s" number="1778" updated="2023-01-11T13:17:44Z">
  <state datetime="2009-10-14">REFERRED</state>
  <status>
    <introduced datetime="2009-10-14"/>
  </status>
  <introduced datetime="2009-10-14"/>
  <titles>
    <title type="display">Access to Affordable Medicines Act</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to generic drugs, and for other purposes.</title>
    <title type="short" as="introduced">Access to Affordable Medicines Act</title>
  </titles>
  <sponsor bioguide_id="S001181"/>
  <cosponsors>
    <cosponsor bioguide_id="B001265" joined="2009-11-02"/>
    <cosponsor bioguide_id="V000127" joined="2009-10-14"/>
  </cosponsors>
  <actions>
    <action datetime="2009-10-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2009-10-14">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S10436-10437"/>
    </action>
    <action datetime="2009-10-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2010-02-26T22:26:49Z" status="Introduced in Senate">Access to Affordable Medicines Act - Amends the Federal Food, Drug, and Cosmetic Act to provide that an application for a generic drug the proposed labeling of which is different from the labeling at the time the Secretary of Health and Human Services (HHS) evaluates the application shall be eligible for approval (and such drug shall not be considered misbranded) if: (1) the revision has been approved by the Secretary within 60 days of the expiration of the patent or exclusivity period for the drug; (2) the Secretary has not determined the applicable labeling text when such period expires; (3) the labeling revision does not include a change to the warnings section; (4) the Secretary does not deem that the continued presence in commerce of the labeling before the revision adversely impacts the safe use of the drug; and (5) the sponsor of the application agrees to submit revised labeling not later than 60 days after the notification of any changes required by the Secretary.</summary>
</bill>
